ABBV (NYSE) - AbbVie Inc
Exchange: USA Stocks • Country: USA • Currency: USD • Type: Common Stock • ISIN: US00287Y1091
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Web URL:
Market Cap. | 251,447m USD |
Enterprise Value | 314,718m USD (+25%) |
GiC Sector | Health Care |
GiC Group | Pharmaceuticals, Biotechnology & Life Sciences |
GiC Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2013-01-02 |
Ratings
Fundamental | 2.21 |
Dividend | 8.51 |
Technical | 5.87 |
Performance | -10.00 |
Analysts | 3.69 |
Price / Fair Price TR | 1.06 |
Price / Fair Price DCF | todo |
Technical
Growth TTM | -5.10% |
CAGR 5y | 11.81% |
CAGR / Mean Drawdown 5y | 1.15 |
Sharpe Ratio TTM | -0.44 |
Alpha vs SP500 TTM | -8.91 |
Beta vs SP500 5y weekly | 0.71 |
Volatility GJR Garch 1y | 24.78% |
CAPM | 8.47% |
Correlation TTM | 0.38 |
Max Drawdown 5y | 35% |
Mean Drawdown 5y | 10.3% |
Price / SMA 200 days | 7.97% |
Current Volume | 7333.4k |
Average Volume | 5728.1k |
Dividends
Rate TTM | 5.78 |
Yield TTM | 4.20% |
Div. CAGR 5y | 9.46% |
Consistency of Dividends all time | 100.0% |